Drug Approval | May 07, 2026
The formulation contains 0.075% Capsaicin, a clinically proven ingredient along with menthol, camphor and eucalyptus oil
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The kidney care provider has established over 40 dialysis centres, delivering more than 40,000 dialysis sessions
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
The approval enables the company to directly sell health insurance plans to individuals and families while integrating its managed healthcare delivery model into retail offerings
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
Subscribe To Our Newsletter & Stay Updated
